bexarotene

Type: Keyphrase
Name: bexarotene
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Investigators from Liaoning University Have Reported New Data on Bexarotene Therapy (Bexarotene nanocrystal-Oral and parenteral formulation...

Investigators from Liaoning University Have Reported New Data on Bexarotene Therapy (Bexarotene nanocrystal-Oral and parenteral formulation development, characterization and pharmacokinetic evaluation) By a News Reporter-Staff News Editor at Biotech Week ... [Published Town Hall - Jul 24 2014]
First reported Jul 20 2014 - Updated Jul 20 2014 - 1 reports

Alzheimer's Needs Cures, Not Pyrrhic Victories

With the clinical trial failure rate for Alzheimer's drugs an astounding 99.6%, major drugmakers have seen one promising Alzheimer's treatment after another fail. The list include Bapineuzumab (Pfizer/Johnson & Johnson), Flurizan (Myriad Genetics), and ... [Published Motley Fool - Jul 20 2014]
First reported Jul 20 2014 - Updated Jul 20 2014 - 1 reports

Bexarotene's effect on Alzheimer's may depend on severity of disease

Ratings require JavaScript to be enabled.A cancer drug that has shown promise against Alzheimer's disease in mice and has begun early clinical trials has yielded perplexing results in a novel mouse model of AD that mimics the genetics and pathology of ... [Published Medical News Today - Jul 20 2014]
First reported Jul 16 2014 - Updated Jul 17 2014 - 3 reports

Drug's effect on Alzheimer's may depend on severity of disease -- ScienceDaily

A cancer drug that has shown promise against Alzheimer's disease (AD) in mice and has begun early clinical trials has yielded perplexing results in a novel mouse model of AD that mimics the genetics and pathology of the human disease more closely than ... [Published DailyMe.Com - Jul 17 2014]
First reported Jul 11 2014 - Updated Jul 11 2014 - 1 reports

Cleveland Clinic researchers identify urgent need for Alzheimer's drug development

Researchers at the Cleveland Clinic Lou Ruvo Center for Brain Health have conducted the first-ever analysis of clinical trials for Alzheimer's disease (AD), revealing an urgent need to increase the number of agents entering the AD drug development pipeline ... [Published World Pharma News - Jul 11 2014]
First reported Jul 07 2014 - Updated Jul 07 2014 - 1 reports

Researchers identify urgent need for Alzheimer's drug development

Current ratings for: Ratings require JavaScript to be enabled.Researchers at the Cleveland Clinic Lou Ruvo Center for Brain Health have conducted the first-ever analysis of clinical trials for Alzheimer's disease (AD), revealing an urgent need to increase ... [Published Medical News Today - Jul 07 2014]
First reported Jul 03 2014 - Updated Jul 04 2014 - 1 reports

Ruvo Center study shows high failure rate for most Alzheimer’s drugs

During the decade 2002-2012, the failure rate for drugs developed to treat Alzheimer’s disease was a woeful 99.6 percent, a study released by the Cleveland Clinic Lou Ruvo Center for Brain Health reveals.That analysis, which found that one drug showed ... [Published Las Vegas Review Journal - Jul 03 2014]
First reported Jul 03 2014 - Updated Jul 03 2014 - 1 reports

Alzheimer's R&D suffers as trial failure rate hits an 'astounding' 99.6%

Jeffrey Cummings is directing one of the few early-stage studies underway on an Alzheimer's therapy. And now that he's scanned the records of clinicaltrials.gov, he's acutely aware of just how small his chosen field is."There are 100 trials of about 80 ... [Published FierceBiotech - Jul 03 2014]
First reported Jun 25 2014 - Updated Jun 25 2014 - 1 reports

Rexinoids Isolated from Sophora tonkinensis with a Gene Expression Profile Distinct from the Synthetic Rexinoid Bexarotene

† Department of Pharmacology of Natural Compounds, Graduate School of Pharmaceutical Sciences, Aichi Gakuin University, 1-100 Kusumoto-cho, Chikusa-ku, Nagoya 464-8650, Japan‡ Department of Pharmaceutical Sciences, Musashino University, 1-1-20 Shinmachi, ... [Published Journal of Natural Products - Jun 25 2014]
First reported Jun 20 2014 - Updated Jun 20 2014 - 1 reports

The Problem of Replication

In 2012, when the journal Science published a study by a group of Cleveland researchers touting a cancer drug’s success against Alzheimer’s disease in mice, it looked like a potential breakthrough in a field long marked by setbacks and failures. As many ... [Published Robb Report - Jun 20 2014]
First reported Apr 09 2014 - Updated Apr 09 2014 - 1 reports

Tumor-initiating cells and methods of use

Provided herein are an isolated or enriched population of tumor initiating cells derived from normal cells, cells susceptible to neoplasia, or neoplastic cells. Methods of use of the cells for screening for anti-hyperproliferative agents, and use of the ... [Published PharmCast - Apr 09 2014]
First reported Feb 14 2014 - Updated Feb 14 2014 - 1 reports

TARGRETIN (Bexarotene) Capsule, Liquid Filled [Valeant Pharmaceuticals North America LLC]

Quotes

"Bexarotene also is extremely toxic to the liver," Tai said. "For prevention, where a drug is given before the symptoms of Alzheimer's disease appear, and likely over longer periods of time, bexarotene is not likely a viable therapeutic because of this known toxicity unless dosing is carefully controlled and patients are closely monitored."
...efforts so often fail," said Jeffrey L Cummings, M D , ScD, Director of the Cleveland Clinic Lou Ruvo CenterLou Ruvo Center for Brain Health. "With an estimated 44 million people living worldwide with the condition, the study shows that the Alzheimer's disease drug development ecosystem needs more support given the magnitude of the problem."
"We need more investment at the NIH, that would re-attract biotech and pharma funding" says Cummings, "then we would see some successes."

More Content

All (15) | News (14) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Investigators from Liaoning University Have Rep... [Published Town Hall - Jul 24 2014]
Alzheimer's Needs Cures, Not Pyrrhic Victories [Published Motley Fool - Jul 20 2014]
Bexarotene's effect on Alzheimer's may depend o... [Published Medical News Today - Jul 20 2014]
Drug's effect on Alzheimer's may depend on seve... [Published DailyMe.Com - Jul 17 2014]
Drug's effect on Alzheimer's may depend on seve... [Published Bio-Medicine - Jul 16 2014]
Drug's effect on Alzheimer's may depend on seve... [Published EurekAlert! - Jul 16 2014]
Cleveland Clinic researchers identify urgent ne... [Published World Pharma News - Jul 11 2014]
Researchers identify urgent need for Alzheimer'... [Published Medical News Today - Jul 07 2014]
Alzheimer's R&D suffers as trial failure rate h... [Published FierceBiotech - Jul 03 2014]
Ruvo Center study shows high failure rate for m... [Published Las Vegas Review Journal - Jul 03 2014]
Rexinoids Isolated from Sophora tonkinensis wi... [Published Journal of Natural Products - Jun 25 2014]
The Problem of Replication [Published Robb Report - Jun 20 2014]
Tumor-initiating cells and methods of use [Published PharmCast - Apr 09 2014]
TARGRETIN (Bexarotene) Capsule, Liquid Filled [... [Published DailyMed Drug Label Updates for the last seven ... - Feb 14 2014]
Mylan announces settlement agreement for first-... [Published Pharmaceutical Business Review - Dec 18 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
TARGRETIN (Bexarotene) Capsule, Liquid Filled [... [Published DailyMed Drug Label Updates for the last seven ... - Feb 14 2014]
Updated Date: Feb 14, 2014 EST ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.